GSK Opens First High-Potency Facility in Singapore for Cancer Treatment Drugs

Jan 2023

British multinational pharmaceutical and biotechnology company GlaxoSmithKline (GSK) has announced the opening of a new SGD 44 million (USD 33 million) high potency facility (HPF) in its strategic New Product Introduction site in Jurong, Singapore. The HPF will be used to produce a key ingredient, which is a cytotoxic component, in antibody drug conjugates (ADCs) to treat cancer.

This facility is the first in Singapore capable of producing highly potent cytotoxic ingredients in ADCs, for breakthrough immunotherapy cancer treatments. It is equipped with advanced features such as specialized equipment, automated operations, containment capabilities and cross-contamination control. It is built to facilitate complete in-house manufacturing to safeguard supply chain processes, quality control and timeliness of delivery. It also features leading-edge capabilities to handle high-potency manufacturing in a safe and controlled environment.

With the addition of the HPF, GSK has further strengthened the Jurong site’s capabilities as a New Product Introduction (NPI) site to launch new products more quickly. The capability to produce high-potency components at scale helps to meet the increasing demand for oncology treatments worldwide.

(Source: GSK)

About Us

Orissa International helps companies that want to develop a market entry strategy for Southeast Asia or implement their business expansion into the region. We have very strong domain knowledge of markets and industry sectors, and a business network of over 16,000 companies that includes distributors, resellers, system integrators and local manufacturers, that we have built through advising and guiding more than 5,000 companies with their market expansion into the ASEAN region over the last 25 years.

Orissa International is headquartered in Singapore, with additional offices in Malaysia, Indonesia, Thailand, Vietnam, and the Philippines.

Our Services